Made-Whole Doctrine Under ERISA: Protecting Clients from Plan Recovery

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

The made-whole doctrine prevents a subrogating party from recovering until the injured person has been fully compensated. Under ERISA, this doctrine applies only when the plan's language is silent — and understanding that gap is critical for pharmacy lien allocation at settlement.

The made-whole doctrine is an equitable principle that prohibits a subrogating health plan from recovering reimbursement until the injured person has been fully compensated for all losses. Under ERISA, the made-whole doctrine applies only when the plan's Summary Plan Description is silent on whether the plan can recover before the beneficiary is made whole — and most sophisticated self-funded plans now include express language overriding it.

• The made-whole doctrine prevents plan subrogation until the plaintiff has recovered full compensation for all damages
• Under ERISA, plan language controls: if the SPD expressly overrides made-whole, the doctrine does not apply (US Airways v. McCutchen, 2013)
• Many older or smaller self-funded plans lack express made-whole override language, creating an opportunity for PI attorneys
• Pharmacy liens are satisfied from net settlement proceeds regardless of made-whole analysis because they represent costs the plan never paid
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that separates lien-funded medication costs from plan-paid expenses for clean settlement allocation

What the Made-Whole Doctrine Means in Practice

The made-whole doctrine originates in equity and insurance law. In states that follow it, the principle is straightforward: a health plan (or insurer) that paid medical benefits cannot recover those payments from a tort settlement unless the settlement fully compensates the injured person for all economic and non-economic damages.

For PI attorneys, the doctrine is a powerful tool when it applies. Consider a client who suffered $200,000 in total damages (medical bills, lost wages, pain and suffering) but settled for $75,000 due to policy limits. Under the made-whole doctrine, the health plan cannot assert subrogation from that $75,000 settlement because the client was not "made whole" — the settlement represents less than full compensation.

The problem is that ERISA preemption complicates this analysis for self-funded employer plans.

[!KEY] The made-whole doctrine is not automatically available against ERISA plans. The Supreme Court in US Airways v. McCutchen, 569 U.S. 88 (2013), held that ERISA plan terms control, and if the plan expressly provides for first-dollar subrogation without a made-whole limitation, that term is enforceable. The doctrine applies only where the plan is silent.

The McCutchen Framework: When Made-Whole Survives

The 2013 McCutchen decision is the controlling authority. The Court held:

1. Express plan terms govern. If the SPD says the plan recovers "from any recovery, regardless of whether the beneficiary has been fully compensated," the made-whole doctrine is overridden.

2. Silence defaults to equity. Where the SPD does not address made-whole — which is more common than many TPAs realize — federal common law equitable principles fill the gap, and the made-whole doctrine applies as a default rule.

3. The common fund doctrine also fills gaps. Where the SPD is silent on whether the plan must contribute to attorney fees, the common fund doctrine applies, reducing the plan's recovery by its pro-rata share of legal costs.

According to James Wong, PharmD, founder of LienScripts, "Every ERISA case requires a careful reading of the SPD before settlement allocation begins. We see cases where the TPA asserts aggressive first-dollar recovery, but the actual plan language is either silent on made-whole or contains ambiguous provisions that an attorney can challenge."

Analyzing SPD Language: What to Look For

PI attorneys should examine the subrogation and reimbursement sections of the SPD for specific language patterns:

Express made-whole override (plan wins):

• "The Plan's right to reimbursement applies regardless of whether the Covered Person has been fully compensated for all damages"
• "The Plan's subrogation right is not subject to any made-whole, make-whole, or full-compensation requirement"

Silent or ambiguous (made-whole may apply):

• The SPD references "reimbursement from any recovery" but does not address whether full compensation is required
• The SPD uses general subrogation language without specifically negating equitable defenses
• The SPD references "equitable subrogation" without defining the term

Favorable language (plan limited):

• "The Plan's recovery is secondary to the Covered Person's full compensation"
• Any language conditioning recovery on the beneficiary being made whole first

[!TIP] Request the full SPD and the plan document — not just the subrogation summary letter from the TPA. TPAs sometimes paraphrase plan language in demand letters more aggressively than the actual SPD supports. Compare the TPA's letter against the verbatim plan text.

Pharmacy Lien Allocation When Made-Whole Applies

When the made-whole doctrine does apply — either because the plan is silent or because the plan is fully insured and state law controls — the settlement allocation becomes more favorable for the client. The plan cannot subrogate at all if the settlement does not fully compensate the client.

Pharmacy liens, however, operate on a different track entirely. The lien is a contractual obligation between the patient, the attorney, and the lien provider. It is not subject to the made-whole analysis because:

1. The lien provider is not a subrogating party. The pharmacy lien provider did not pay the patient's medical expenses and then seek reimbursement — it advanced medication costs under a lien agreement that creates a direct repayment obligation.

2. The lien is satisfied from net proceeds. The pharmacy lien is paid from the client's share of the settlement, not from the plan's subrogation recovery. There is no competition between the two.

3. The made-whole doctrine protects against the plan, not the lien. When made-whole eliminates or reduces the plan's subrogation claim, the client retains more of the settlement — which means more funds available to satisfy the pharmacy lien and increase the client's net recovery.

The MERIT report from LienScripts documents every lien-funded medication with clinical justification, providing clear evidence that these costs are separate from plan-paid expenses and outside the subrogation analysis entirely.

Practical Litigation Strategy

When made-whole applies (plan is silent):

• Assert the doctrine in your response to the TPA's subrogation demand
• Demonstrate that the settlement does not fully compensate the client for all damages
• The plan's recovery is reduced to zero if the client is not made whole, or reduced proportionally if the client is partially compensated
• The pharmacy lien is satisfied from net proceeds without any impact from the made-whole analysis

When made-whole is overridden (plan has express language):

• Shift to McCutchen common fund arguments to reduce the plan's net recovery
• Preserve Montanile dissipation arguments as additional leverage
• The pharmacy lien remains unaffected because it covers costs the plan never paid

[!KEY] The made-whole doctrine is most valuable in cases where the settlement is below full damages value — which is most PI cases. Even when the doctrine is unavailable against the ERISA plan, pharmacy liens remain protected because they represent a separate cost category. The two analyses are independent.

Combining Made-Whole with Pharmacy Lien Strategy

The strongest client outcomes occur when attorneys combine made-whole arguments (where available) with proactive pharmacy lien enrollment:

1. Made-whole reduces or eliminates the plan's subrogation claim on medical costs the plan paid
2. Pharmacy lien keeps medication costs outside the plan's reach entirely — no subrogation argument needed
3. The client retains the maximum net recovery because the settlement is not depleted by both full ERISA subrogation and medication costs

This combined approach requires early case planning — identifying ERISA status, analyzing SPD language, and enrolling in a pharmacy lien — all at intake.

Related Resources

• ERISA Preemption and Pharmacy Liens: Attorney Guide
• ERISA Common Fund Doctrine and Pharmacy Recovery
• ERISA Plan Language Analysis for Pharmacy Liens
• ERISA Self-Funded Plan Defense for Pharmacy Liens